Ravidasvir 200mg

DRUG2 trials

Sponsors

Ascletis Pharmaceuticals Co., Ltd., Muhammad Radzi Abu Hassan

Conditions

Chronic Hepatitis cHepatitis C

Phase 1

A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

CompletedNCT03430830

Ascletis Pharmaceuticals Co., Ltd.Chronic Hepatitis c

Start: 2018-01-15End: 2018-04-09Updated: 2018-06-29

Phase 2

8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C

CompletedNCT04885855

Muhammad Radzi Abu HassanHepatitis C

Start: 2021-03-23End: 2024-03-15Updated: 2025-03-13

Related Papers

Time to viral load suppression with 8-week versus 12-week ravidasvir/sofosbuvir regimens among chronic hepatitis C patients in Malaysia: a non-inferiority, randomized clinical trial

BMC Infectious Diseases2026-06-11

Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects.

2021-07-122 citations